84 results about "Albumin solution" patented technology

Antitumor formulation based on nanoparticles of paclitaxel and human serum albumin as obtained by the addition of a biocompatible acid to an aqueous albumin solution before this is mixed with paclitaxel during the nanoparticle production process, the injectable solutions of this formulation having a pH between 5.4 and 5.8 and having stability and inalterability with time.

The present invention features that the bilirubin adsorbent is synthesized by selecting well biocompatible polystyrene-divinylbenzene copolymer as carrier, PHEMA as coating agent, epichlorohydrin for activating the functional hydroxy radical of PHEMA, and glutaraldehyde as cross-linking agent for cross-linking functional cyclodextrin molecule. The bilirubin adsorbent has biocompatibility and adsorption capacity superior to active carbon and cationic resin adsorbing material, and has no adsorbent molecule falling resulting in immunological dysfunction. Animal experiment shows that the novel bilirubin adsorbent may be used to eliminate bilirubin from blood, blood plasma and albumin solution effectively.

An arsenic compound solution, and an albumin nanoparticle and a lyophilized preparation prepared using same and entrapping an arsenic compound. The arsenic compound solution is prepared using the following method: adding As₂O₃ powder in sterile deionized water to obtain a suspension, 6 to 25 mg of As₂O₃ powder being added in every mL of sterile deionized water; dripping an NaOH solution to the obtained suspension until the powder is fully dissolved and adjusting the pH of the solution to 7.5 to 9, and making the concentration of the obtained arsenic compound solution be 5 to 20 mg/mL in terms of the added As₂O₃. The albumin nanoparticle is prepared by mixing an albumin solution and the arsenic solution and the arsenic solution with the mass ratio of the added As₂O₃ in arsenic compound solution to the albumin ranging from 1:5 to 1:20 and using a method of solvent removing and physical curing.

The invention discloses a bovine serum albumin extraction method which comprises the following steps: first concentration and liquid exchange: conducting ultrafiltration concentration on a protein dissolution solution through a first ultrafiltration membrane to obtain a protein concentrate; first purification: conducting chromatographic purification collection on the protein concentrate through a weak anion exchange medium to obtain a crude albumin solution; second concentration and liquid exchange: conducting ultrafiltration concentration on the crude albumin solution through a second ultrafiltration membrane to obtain a crude albumin concentrate; second purification: conducting chromatographic purification collection on the crude albumin concentrate through a strong cation exchange medium to obtain an albumin solution. According to the extraction method, through the steps of two times of ultrafiltration concentration and two times of chromatographic purification, impurities in blood plasma can be removed to the maximum extent, and the purity of the bovine serum albumin is improved. Besides, the invention also provides bovine serum albumin obtained through the method.

The invention relates to a non-programmable-controlled cooling cryopreservation method and a protection agent for hematopoietic stem cells at minus 80DEG C. The protection agent consists of 5 parts by volume of reagent A and 2 parts by volume of reagent B, wherein the reagent A is a dimethyl sulfoxide and hydroxyethyl starch solution, wherein the mass percents of the dimethyl sulfoxide and hydroxyethyl starch are 10 to 20 percent and 5.4 to 6 percent respectively, the reagent B is an albumin solution, and the mass percent of the albumin is 20 to 40 percent. The formula of the protection agent is simple, and raw materials are cheap; by adopting the preservation method, the hematopoietic stem cells can be simply and conveniently stored under the minus 80-DEG C non-programmable-controlled cooling condition, the survival rate of the stored cells is higher than 90 percent, and the method is suitable for being clinically popularized and applied and used for preserving the clinic hematopoietic stem cells at the low temperature of minus 80DEG C for a short time.

The present invention discloses a single-stranded DNA nucleic acid modified chitosan magnetic microsphere preparation method, which comprises: (1) adopting a chemical co-precipitation method to obtain Fe3O4 magnetic nanoparticles; (2) adopting an inverse emulsion cross-linking method to obtain CS/Fe3O4 magnetic microspheres; (3) adding the CS/Fe3O4 magnetic microspheres to APTES to obtain -NH2 modified CS/Fe3O4 magnetic microspheres; (4) adding DTPA to obtain -COOH modified CS/Fe3O4 magnetic microspheres under effects of EDC and NHS; and (5) adding EDC and other solutions, adding a bovine albumin solution, and shaking to obtain the adenosine aptamer modified CS/Fe3O4 magnetic microspheres. According to the present invention, the disadvantages of easy shedding, instability and the like of the conventional physical adsorption method are overcome, and the immobilization amount of the aptamer is significantly increased.

The invention discloses a preparation method and a using method of a hydrophilic adhesive glass slide. The preparation method comprises the following steps: pre-processing the glass slide by using amino silane solutions with the volume concentration of 0.8-8 percent or polylysine solutions with the volume concentration of 0.1-1 percent; washing; airing; soaking the aired glass slide into albumin solutions with the mass concentration of 0.5-5 percent; taking out; washing; and airing to obtain the hydrophilic adhesive glass slide. The hydrophilic adhesive glass slide has hydrophilic groups on the surface, and is compatible with biological macromolecules and high in adhesion property; waterborne reagents are easily and uniformly spread on the surface of the glass slide, so that the defect that a common adhesive glass slide is always unevenly stained when used on an immunohistochemistry autostainer are overcome.

The invention provides a folic acid quantitative detection kit suitable for all kinds of fully automatic biochemical analyzer, wherein the kit includes a reagent R1, a reagent R2, a calibration product and a quality control product. The reagent R1 includes a folic acid binding albumin solution, and the reagent R2 includes a folic acid antibody latex particle suspension. The folic acid quantitativedetection kit can quickly quantitatively detect the content of folic acid in whole blood, erythrocytes and serum in ten minutes, has the advantages of high specificity, high sensitivity and simple operation. In addition, the kit has reasonable preparation cost, and can be used in batches in clinic.

The invention relates to an albumin-purification method comprising a step consisting in subjecting an aqueous albumin solution, with a concentration of between 15 g/l and 80 g/l and a pH of not less than 7, to nanofiltration in a temperature range of between 15 DEG C. and 55 DEG C. The invention also relates to: a virally-safe aqueous albumin solution which can be obtained using the invention method and in which the sites for the transport and binding of the active therapeutic ingredients of the albumin are available; and an albumin composition for therapeutic use, which is obtained by adapting the albumin solution that is intended for clinical use.

The present invention provides a method of polishing albumin to remove contaminants comprising passing an albumin enriched solution through a hydrophobic charge-induction chromatographic resin and recovering the albumin solution which passes through the resin. Also provided is a polished albumin solution prepared by said method.

The invention provides a stable aseptic lyophilized cabazitaxel composition, and a preparation method thereof. The prescription and the preparation technology of the above preparation are screened, so the cabazitaxel and albumin composition prepared from a low concentration of an albumin solution has the characteristics of good stability and good safety, and also has the advantages of no use of water-insoluble chloroform/dichloromethane or other highly toxic organic solvents in the preparation process, no addition of a lyophilization protection agent or a protein stabilizer in a lyophilizing step, reduction of the medicine production cost, and guaranteeing of the safety of clinic medication.

The invention discloses a portable multiple organ support integration machine which comprises an arterial closed circuit, a venous closed circuit, an albumin solution return circuit, a fluid infusion closed circuit and an ultrafiltrate closed circuit. A self-balance replacement device adopting a hard-type cavity and a hard-type piston is arranged on the fluid infusion closed circuit and the ultrafiltrate closed circuit, and flow balance of the fluid infusion closed circuit and the ultrafiltrate closed circuit is maintained by a method of volume replacement. The problems that existing multiple organ support integration machines are large in size, difficult to carry, poor in portability and hard for staff not in the profession to use, and cannot be used for treating and curing in special environments like in sports.

The invention relates to a preparation process for glycyrrhizic acid-mediated hydroxycamptothecine albumin liver cancer targeting nanoparticle lyophilized powder. The glycyrrhizic acid-mediated hydroxycamptothecine albumin liver cancer targeting nanoparticle lyophilized powder is obtained by the steps of reacting glycyrrhizic acid and albumin under a certain conditions to successfully couple glycyrrhizic acid and albumin; removing glycyrrhizic acid uncoupled with albumin by a dialysis method; then lyophilizing albumin coupled with glycyrrhizic acid to obtain lyophilized powder of albumin coupled with glycyrrhizic acid; dissolving albumin coupled with glycyrrhizic acid in water at a certain concentration and hydroxycamptothecine in a mixed solution of chloroform and ethanol; dropwise adding the hydroxycamptothecine solution to the albumin solution slowly; homogenizing at a certain rotation speed and time; homogenizing the homogenized mixed suspension for a certain times under a certain pressure to obtain an oil-in-water emulsion; removing organic solvents-ethanol and chloroform from the mixed suspension by a rotary evaporation method; and then removing water from the mixed suspension in a lyophilization manner.

The invention discloses a method for forming an albumen layer by mediating albumin on the surface of a material, a biological material and application thereof and relates to the technical field of biomaterials. The method for forming an albumen layer by mediating albumin on the surface of a material includes standing a to-be-supported material in an alkaline solution and then obtaining an alkali-activated material; fixing dendrimers on the surface of the alkali-activated material, and then immersing the modified material in an albumin solution for standing reaction. Preferably, the dendrimer is a polyamide-amine dendrimer PAMAM; and more preferably, the molecular weight of PAMAM is 6000 to 10000. The biological material forms a PAMAM layer and the albumin layer on the surface of the to-be-supported material, and the albumin is mediated to form the albumen layer. The biological material is used for preparing a cardiovascular implant material and can reduce the adhesion of platelets to achieve anticoagulation, and the biocompatibility of the material is improved.

The present invention discloses a kit and a method for separating mononuclear cells from umbilical cord blood. The kit for separating the mononuclear cells from the umbilical cord blood comprises the following components: a dilution solution which is a sodium chloride solution with the mass percentage of 0.1% to 5% or a phosphate buffer with pH of 7 to 7.5; a precipitating agent which is a hydroxyethyl starch solution with the mass percentage of 2.4%-12%, a hydroxymethyl starch solution with the mass percentage of 2.4%-12% or a methyl cellulose solution with the mass percentage of 2.4%-12%; a resuspension solution which is an albumin solution with the concentration of 5 to 10% or human AB blood plasma with the concentration of 10-30%; and a separation liquid which is a silica gel particle suspension treated by polyvinylpyrrolidone, and the separation liquid has a density of 1.072-1.086g / ml. The kit and the method can effectively separate and save the mononuclear cells, and have good application prospect. The effect is better than that of commercially available kits.

The invention relates to a separation technology for plasma protein through a low-temperature ethanol method. The two-step low-temperature ethanol separation method is adopted for separating a human blood albumin product. The technology is characterized in that the step of separating a component IV precipitate does not exist in the low-temperature ethanol separation technology for the human bloodalbumin, after components I, II and III are precipitated, the component V precipitate is directly separated, the ultrafiltration process for a human blood albumin solution is a two-step ultrafiltration technology, firstly, an ultrafiltration filtrate is reserved through ultrafiltration, macromolecule impure protein is removed through ultrafiltration, and then the human blood albumin is subjected to ultrafiltration to remove micromolecule protein, residual ethyl alcohol and possible aluminium ions. The technology has the advantages that the high yield of the human blood albumin product is fundamentally guaranteed, the possibility of repeated production or the reproduction process in the production technology of the human blood albumin is completely eliminated, and it is guaranteed that production of a blood product more effectively meets the demand of GMP for the medicine.

The invention provides a method for preparing an albumin-based polyacrylic acid nano-carrier, which uses biological macromolecule bovine serum albumin with strong hydrophilicity and good biocompatibility as a template, and makes use of a method in which acrylic acid in an albumin solution has self-assembly and further has in situ polymerization to successfully prepare nano-scale bovine serum albumin-based polyacrylic acid nanospheres and nanocapsules. The structures and the shapes of the prepared nanoshperes and the nanocapsules are characterized through a nanometer particle diameter instrument (DLS), an infrared absorption spectroscoper (FT-IR), UV-Vis spectrometer and transmission electron microscope (TEM) to find that the particle diameter of the nanoparticles is between 80 and 100 nanometers, the external diameter of the nanocapsules is between 300 and 400 nanometers, and the inner diameter thereof is about between 100 and 200 nanometers. The nanospheres and the nanocapsules are provided with positive charges on the surfaces and have pH sensitivity; the controllable release property of medicament doxorubicin is up to 150 hours; and the nanospheres and the nanocapsules are used for medicament carriers with strong toxicity and poor stability to achieve the controllable release of such medicaments so as to endow the medicaments with targeting property, improve the medicament efficacy, and reduce the toxicity and the side effects.